Everything below concerns c-Met receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
== History == Mobile refrigeration with ice from the ice trade began with reefer ships and refrigerator cars (iceboxes on wheels) in the mid-19th century. The term cold chain was first used in 1908. The first effective cold store in the UK opened in 1882 at St Katharine Docks. It could hold 59,000 carcasses, and by 1911 cold storage capacity in London had reached 2.84 million carcasses. By 1930 about a thousand refrigerated meat containers were in use which could be switched from road to railway. Mobile mechanical refrigeration was invented by Frederick McKinley Jones, who co-founded Thermo King with entrepreneur Joseph A. "Joe" Numero. In 1938 Numero sold his Cinema Supplies Inc. movie sound equipment business to RCA to form the new entity, U.S. Thermo Control Company (later the Thermo King Corporation), in partnership with Jones, his engineer. Jones designed a portable air-cooling unit for trucks carrying perishable food, for which they obtained a patent on 12 July 1940, subsequent to a challenge to invent a refrigerated truck over a 1937 golf game by associates of Numero's, Werner Transportation Co. president Harry Werner, and United States Air Conditioning Co. president Al Fineberg, This technology has been frequently in use since the 1950s, when it was most often used for preserving animal-based cells or tissue. As medical breakthroughs, such as in cancer treatment, have taken place, the demand for cold chain systems has grown. The COVID-19 pandemic and its associated vaccinations, have caused vastly increased need.
=== Survival during freeze-drying processes === In 2017, a study was done to see the effects of six different substances on the growth and freeze- drying of Lactobacillus. Using Lactobacillus as starter cultures for the dairy industry depends on the number of viable and active cells. Currently, the preferred method to preserve the bacterial cells is through freeze-drying, however this also results in some strains being killed. This is due to various complications of freeze-drying, including the formation of ice crystals, loss of membrane fluidity, and the denaturation of important macromolecules. Regardless, freeze-drying has been used for decades in microbiological research as a way to store and stabilize cultures. Six substances, being sodium chloride, sorbitol, mannitol, mannose, monosodium glutamate, and betaine were tested to determine if they had any effect on the survivability of the cells after freeze-drying. Three of the six substances added had a positive effect on the growth and freeze-drying of Lactobacillus, being sodium chloride, sorbitol, and sodium glutamate. The results suggest that these substances have protective effects on Lactobacillus delbrueckii subsp. bulgaricus in small concentrations, but have little effect or even some harmful effects in higher concentrations. The optimal concentrations for sorbitol, sodium chloride and sodium glutamate for the desired protective effects were 0.15%, 0.6%, and 0.09% respectively. This was shown to increase cell viability drastically.
5,000–7,200 species of red algae worldwide "some 1,300 in Australian Seas" 400 seaweed species for the western coastline of South Africa, and 212 species from the coast of KwaZulu-Natal. Some of these are duplicates, as the range extends across both coasts, and the total recorded is probably about 500 species. Most of these are listed in List of seaweeds of South Africa. These exclude phytoplankton and crustose corallines. 669 marine species from California (US) 642 in the check-list of Britain and Ireland and so on, but lacking any scientific basis or reliable sources, these numbers have no more credibility than the British ones mentioned above. Most estimates also omit microscopic algae, such as phytoplankton.
=== HCG diet === British endocrinologist Albert T. W. Simeons proposed HCG as an adjunct to an ultra-low-calorie weight-loss diet (fewer than 500 calories). Simeons, while studying pregnant women in India on a calorie-deficient diet, and obese boys with pituitary issues (Frölich's syndrome) treated with low-dose HCG, observed that both lost fat rather than lean (muscle) tissue. He reasoned that HCG must be programming the hypothalamus to do this in the former cases in order to protect the developing fetus by promoting mobilization and consumption of abnormal, excessive adipose deposits. Simeons in 1954 published a book entitled Pounds and Inches, designed to combat obesity. Simeons, practicing at Salvator Mundi International Hospital in Rome, Italy, recommended low-dose daily HCG injections (125 IU) in combination with a customized ultra-low-calorie (500 cal/day, high-protein, low-carbohydrate/fat) diet, which was supposed to result in a loss of adipose tissue without loss of lean tissue. Other researchers did not find the same results when attempting experiments to confirm Simeons' conclusions, and in 1976 in response to complaints the FDA required Simeons and others to include the following disclaimer on all advertisements:
=== Amputation methods === Throughout Europe, there were varying approaches when it came to amputations. The two main considerations for amputation procedures were how fast it could be performed and how it would heal. The mallet-and-wedge technique involved setting the body part on a wedge and hitting the wedge with a mallet. This separated the limb or digit from the body by crushing it. This method was very fast but left a messy result that caused the crushed bones to splinter into the remaining part of the limb. The hand's-width method used a curved knife to cut through the limb's tissue, and a bow-frame saw to cut through the bone. An assistant would pull the flesh upwards to expose the bone. After the limb was sawed off, the flesh would then be pulled back over the stump to create a cushion. This procedure took longer but healed more easily. One method to stop hemorrhaging after amputation was iron cautery. This involved taking hot iron instruments to the new stump and burning off the exposed tissue, closing the blood vessels. Another method of cauterization was to apply corrosive chemicals to the fresh wound to burn the blood vessels and stop the bleeding. Both methods were efficient but led to a long healing process. A different method was ligation. This technique required the surgeon to draw out the individual blood vessels and tie them shut. This process was much more time-consuming but healed more quickly. There was also debate among barber-surgeons on the location of amputation.
Sources: en.wikipedia.org
== Role in disease == It has been shown that GSNOR may have an important role in respiratory diseases such as asthma. GSNOR expression has been inversely correlated with S-nitrosothiol (SNO) levels in the alveolar lining fluid in the lung and with responsiveness to methacholine challenge in patients with mild asthma compared to normal subjects. Furthermore, there are lowered SNOs in tracheal irrigations in asthmatic children with respiratory failure in comparison to normal children undergoing elective surgery and NO species are elevated in asthma patients when exposed to antigen. Assessing the gene expression of the ADHs in nonalcoholic steatohepatitis (NASH) patients has shown elevated levels of all ADHs, but primarily ADH1 and ADH4 (up to 40-fold increased). ADH5 showed a ~4-fold increase in gene expression.
Information found in PPIs databases supports the construction of interaction networks. Although the PPI network of a given query protein can be represented in textbooks, diagrams of whole cell PPIs are frankly complex and difficult to generate. One example of a manually produced molecular interaction map is the Kurt Kohn's 1999 map of cell cycle control. Drawing on Kohn's map, Schwikowski et al. in 2000 published a paper on PPIs in yeast, linking 1,548 interacting proteins determined by two-hybrid screening. They used a layered graph drawing method to find an initial placement of the nodes and then improved the layout using a force-based algorithm. Bioinformatic tools have been developed to simplify the difficult task of visualizing molecular interaction networks and complement them with other types of data. For instance, Cytoscape is an open-source software widely used and many plugins are currently available. Pajek software is advantageous for the visualization and analysis of very large networks. Identification of functional modules in PPI networks is an important challenge in bioinformatics. Functional modules means a set of proteins that are highly connected to each other in PPI network. It is almost similar problem as community detection in social networks. There are some methods such as Jactive modules and MoBaS. Jactive modules integrate PPI network and gene expression data where as MoBaS integrate PPI network and Genome Wide association Studies.
Based on a precautionary approach, WHO recommends focusing control of exposure on preventing inhalation exposure with the aim of reducing it as much as possible (strong recommendation, moderate-quality evidence). WHO recommends reduction of exposures to a range of MNMs that have been consistently measured in workplaces especially during cleaning and maintenance, collecting material from reaction vessels and feeding MNMs into the production process. In the absence of toxicological information, WHO recommends implementing the highest level of controls to prevent workers from any exposure. When more information is available, WHO recommends taking a more tailored approach (strong recommendation, moderate-quality evidence). WHO recommends taking control measures based on the principle of hierarchy of controls, meaning that the first control measure should be to eliminate the source of exposure before implementing control measures that are more dependent on worker involvement, with PPE being used only as a last resort. According to this principle, engineering controls should be used when there is a high level of inhalation exposure or when there is no, or very little, toxicological information available. In the absence of appropriate engineering controls PPE should be used, especially respiratory protection, as part of a respiratory protection programme that includes fit-testing (strong recommendation, moderate-quality evidence).
Fischer (born 1979/1980), American chemist notable for work on the WE-CAN project and on peroxyacetyl nitrate Ernst Gottfried Fischer (1754–1831), German chemist who proposed a system of equivalents based on sulfuric acid equal to 1000 Ernst Otto Fischer (1918–2007), German chemist, 1973 Nobel Prize in Chemistry for pioneering work on organometallic chemistry Franz Joseph Emil Fischer (1877–1947), German chemist, co-discovered the Fischer–Tropsch process Hans Fischer (1881–1945), German organic chemist, 1930 Nobel Prize in Chemistry for research on the constitution of haemin and chlorophyll Nellie Ivy Fisher (1907–1995), London-born industrial chemist known for photographic chemistry Wilhelm Rudolph Fittig (1835–1910), German chemist, co-discovered Wurtz–Fittig reaction
Two pharmacological agents intended to prevent scarring in mild idiopathic fibrosis are pirfenidone, which reduced reductions in the 1-year rate of decline in FVC and reduced the decline in distances on the 6-minute walk test, but had no effect on respiratory symptoms, and is nintedanib, which acts as an antifibrotic, mediated through the inhibition of a variety of tyrosine kinase receptors (including platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor). A randomized clinical trial showed it reduced lung-function decline and acute exacerbations. Preclinical studies on monoclonal antibodies that target the pulmonary endothelial aggregation receptor 1 (PEAR1) (which plays a crucial role in fibroblast activation and the progression of fibrosis) have shown promising results in slowing disease progression and improving lung function. Anti-inflammatory agents have only limited success in reducing the fibrotic process. Some other types of fibrosis, such as non-specific interstitial pneumonia, may respond to immunosuppressive therapy such as corticosteroids. But only a minority of patients respond to corticosteroids alone, so additional immunosuppressants, such as cyclophosphamide, azathioprine, methotrexate, penicillamine, and cyclosporine may be used. Colchicine has also been used with limited success. Nerandomilast (Jascayd) was approved for medical use in the United States in October 2025.
Sources: en.wikipedia.org
==== Parkinson's disease ==== Creatine's impact on mitochondrial function has led to research on its efficacy and safety for slowing Parkinson's disease. As of 2014, the evidence did not provide a reliable foundation for treatment decisions, due to risk of bias, small sample sizes, and the short duration of trials.
Evidence for depression being causally associated with isotretinoin use includes 41 reports of positive challenge/dechallenge/rechallenge with isotretinoin, involving administering isotretinoin, withdrawing the drug, and then re-administering it. The majority of these cases had no psychiatric history. There is also a temporal relationship between the development of depression and initiation of isotretinoin treatment, with most cases developing after 1–2 months of treatment. Further, higher doses of isotretinoin increase the risk of developing depression, with 25% of people showing depression on a dose of 3 mg/kg/day as compared with 3–4% at normal doses. Studies have uncovered several biological processes which may credibly explain the affective changes induced by isotretinoin.
The penile raphe is the visible ridge between the lateral halves of the penis, found on the ventral or underside of the penis, running from the meatus and continuing as the perineal raphe across the scrotum and the perineum (area between scrotum and anus). The human penis differs from those of most primates, as it has no baculum and relies entirely on erectile tissue. A distal ligament buttresses the glans penis and plays an integral role to the penile fibroskeleton, and the structure is called "os analog", a term coined by Geng Long Hsu in the Encyclopedia of Reproduction. It is a remnant of the baculum that has likely evolved due to change in mating practice. The human penis cannot be withdrawn into the groin, and it is larger than average in the animal kingdom in proportion to body mass. The human penis is reciprocating from a cotton soft to a bony rigidity resulting from penile arterial flow varied between 2–3 to 60–80 mL/Min implies the most ideal milieu to apply Pascal's law in the entire human body; the overall structure is unique.
=== Limitations === While the high-selectivity and tight-binding of RNA aptamers have generated interest in their use as pharmaceuticals, there are many problems which have prevented them from being successful in vivo. For one, without modifications RNA aptamers are degraded after being introduced into the body by nucleases in the span of a few minutes. Also, due to their small size, RNA aptamers can be removed from the bloodstream by the renal system. Because of their negative charge, RNA aptamers are additionally known to bind proteins in the bloodstream, leading to non-target tissue delivery and toxicity. Care must also be taken when isolating the RNA aptamers, as aptamers which contain repeated Cytosine-Phosphate-Guanine (CpG) sequences will cause immune system activation through the Toll-like receptor pathway. In order to combat some of the in vivo limitations of RNA aptamers, various modifications can be added to the nucleotides to aid in efficacy of the aptamer. For instance, a polyethylene glycol (PEG) moiety can be attached to increase the size of the aptamer, thereby preventing its removal from the bloodstream by the renal glomerulus. However, PEG has been implicated in allergic reactions during in vivo testing. Furthermore, modifications can be added to prevent nuclease degradation, such as a 2’ fluoro or amino group as well as a 3’ inverted thymidine. Additionally, the aptamer can be synthesized so that the ribose sugar is in the L-form instead of the D-form, further preventing nuclease recognition. Such aptamers are known as Spiegelmers.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.